Search results for "22"

showing 10 items of 13984 documents

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct

Heat shock protein: a hot topic in idiopathic pulmonary fibrosis

2017

HSP90 inhibition could be an exciting new treatment strategy for IPF http://ow.ly/HfKY306uvxw

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyPulmonary Fibrosis03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineHeat shock proteinPulmonary fibrosismedicineHumansHeat-Shock Proteinsbiologybusiness.industrymedicine.diseaseImmunohistochemistryHsp90Idiopathic Pulmonary Fibrosis030104 developmental biology030228 respiratory systemImmunologybiology.proteinImmunohistochemistryTreatment strategybusinessEuropean Respiratory Journal
researchProduct

P285 The ‘real-life’ copd patient in the age of laba/lamas: an expansion of the daccord study

2016

Introduction The prospective, non-interventional DACCORD study collects data from a representative cohort of COPD out-patients across Germany who either initiated or changed COPD maintenance medication prior to entry. Initially, DACCORD consisted of two treatment groups (Glycopyrronium-based therapy vs. any other COPD maintenance medication with the exception of Glycopyrronium). Following the approval of LABA/LAMA fixed-dose combinations (FDC) in 2013, DACCORD was extended to follow an additional cohort of patients receiving any LABA/LAMA FDC over a period of 2 years. Methods 5223 patients with complete baseline data (3815 LAMA/LABA FDC vs. 1408 standard treatment group) were analysed here.…

0301 basic medicinePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyeducation.field_of_studyCOPDExacerbationbiologybusiness.industryStandard treatmentPopulationLamamedicine.diseasebiology.organism_classificationObstructive lung disease03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory systemConcomitantCohortmedicineeducationbusinessThorax
researchProduct

Bacterial-viral load and the immune response in stable and exacerbated COPD: significance and therapeutic prospects.

2016

Silvestro Ennio D’Anna,1 Bruno Balbi,2 Francesco Cappello,3,4 Mauro Carone,2 Antonino Di Stefano21Department of Rehabilitation, Cardiorespiratory Unit, Fondazione Istituto G. Giglio di Cefalù, 2Pneumology Unit and Laboratory of Cytoimmunopathology of Heart and Lung, Fondazione Salvatore Maugeri, IRCCS, Veruno (NO) and Cassano delle Murge (BA), 3Human Anatomy Section, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy; 4Euro-Mediterranean Institute of Science and Technology, Palermo, ItalyAbstract: Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and an abnormal inflammatory respon…

0301 basic medicinePulmonary and Respiratory MedicinePulmonary diseasemicrobiomeReview03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineImmune systemexacerbationsmedicineHumansMicrobiomeRespiratory systemlcsh:RC705-779COPDImmunity CellularLungseverity of COPDbusiness.industryBiomarkers; COPD phenotype; Exacerbations; Microbiome; Severity of COPD; Pulmonary and Respiratory Medicine; Public Health Environmental and Occupational Health; Health PolicyHealth PolicyPublic Health Environmental and Occupational HealthbiomarkersExacerbationlcsh:Diseases of the respiratory systemBiomarkerGeneral MedicineViral Loadmedicine.diseaseBacterial Loadrespiratory tract diseases030104 developmental biologymedicine.anatomical_structure030228 respiratory systemImmunologyDisease ProgressionCOPD phenotypebusinessViral loadRespiratory tractInternational journal of chronic obstructive pulmonary disease
researchProduct

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell l…

2019

Abstract Objectives To evaluate the effect on quality of life (QOL) of the addition of cisplatin to single-agent chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) enrolled in two parallel phase 3 trials, MILES-3 and MILES-4. Patients and methods Advanced NSCLC pts, >70 years old, performance status (PS) 0–1, were eligible. Patients were randomly assigned to chemotherapy without or with cisplatin. EORTC QLQ C30 and LC13 questionnaires were planned at baseline, end of cycle 1 and end of cycle 2 in both trials and were used for joint QOL analysis. Trial-specific data including questionnaires at non-shared time-points were used for additional ana…

0301 basic medicinePulmonary and Respiratory MedicineQuality of lifeMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNauseamedicine.medical_treatmentRandomizedNSCLCPhase 303 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurveys and QuestionnaireLung cancerAgedNeoplasm StagingCisplatinAged 80 and overChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryAlopeciamedicine.diseaseDysphagiaLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisVomitingStomatitis AphthousFemalemedicine.symptomCisplatinbusinessElderly patientStomatitis Aphthoumedicine.drugHuman
researchProduct

Staphylococcus aureusand its IgE-inducing enterotoxins in asthma: current knowledge

2020

While immunoglobulin (Ig) E is a prominent biomarker for early-onset, its levels are often elevated in non-allergic late-onset asthma. However, the pattern of IgE expression in the latter is mostly polyclonal, with specific IgEs low or below detection level albeit with an increased total IgE. In late-onset severe asthma patients, specific IgE to Staphylococcal enterotoxins (se-IgE) can frequently be detected in serum, and has been associated with asthma, with severe asthma defined by hospitalisations, oral steroid use and decrease in lung function. Recently,se-IgE was demonstrated to even predict the development into severe asthma with exacerbations over the next decade.Staphylococcus aureu…

0301 basic medicinePulmonary and Respiratory Medicinebiologybusiness.industrymedicine.medical_treatmentInnate lymphoid cellDegranulationEosinophilImmunoglobulin E03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCytokine030228 respiratory systemMucosal immunologyImmunologySuperantigenbiology.proteinMedicineAntibodybusinessEuropean Respiratory Journal
researchProduct

P1.13-16 The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis

2018

0301 basic medicinePulmonary and Respiratory Medicinebusiness.industryDiagnostic accuracyEGFR T790M03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCirculating tumor DNA030220 oncology & carcinogenesisMeta-analysisMutation (genetic algorithm)Cancer researchMedicinebusinessJournal of Thoracic Oncology
researchProduct

71P Exosomes isolated in plasma of non-small cell lung cancer patients contain microRNA related to the EGFR pathway: Proof of concept

2016

0301 basic medicinePulmonary and Respiratory Medicinebusiness.industrymedicine.diseaseMicrovesiclesCell biology03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesismicroRNAmedicineEgfr signalingNon small cellLung cancerbusinessJournal of Thoracic Oncology
researchProduct

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, “down but not out.” VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, …

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyAdministration OralClinical settingsVitamin kCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineOral anticoagulationCerebral Hemorrhagebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismSafety profile030104 developmental biologyTreatment modalityvenous thromboembolism oral anticoagulation warfarin non-VKA oral anticoagulants safety efficacy030220 oncology & carcinogenesisWarfarinbusinessVenous thromboembolismmedicine.drug
researchProduct

Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases

2019

The pathogenetic role of angiogenesis in interstitial lung diseases (ILDs) is controversial. This study represents the first investigation of the spatial complexity and molecular motifs of microvascular architecture in important subsets of human ILD. The aim of our study was to identify specific variants of neoangiogenesis in three common pulmonary injury patterns in human ILD.We performed comprehensive and compartment-specific analysis of 24 human lung explants with usual intersitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) and alveolar fibroelastosis (AFE) using histopathology, microvascular corrosion casting, micro-comupted tomography based volumetry and gene expression…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyAngiogenesisVascular remodelling in the embryoNeovascularization03 medical and health sciences0302 clinical medicineVascularitymedicineHumansIdiopathic Interstitial PneumoniasLungIdiopathic interstitial pneumoniaLungNeovascularization Pathologicbusiness.industryrespiratory systemmedicine.diseaserespiratory tract diseases3. Good healthPneumonia030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisHistopathologymedicine.symptomLung Diseases InterstitialTomography X-Ray ComputedbusinessEuropean Respiratory Journal
researchProduct